Clinical Report: Complete Remission of Catatonia and Psychotic Symptoms in a Parkinson's Disease Patient with Acromegaly Following Lorazepam Treatment
Overview
This case study reports the complete resolution of catatonia and psychotic symptoms in a 78-year-old woman with Parkinson's disease and acromegaly following lorazepam treatment. The findings underscore the potential effectiveness of lorazepam in managing complex neuropsychiatric symptoms in patients with Parkinson's disease.
Background
Parkinson's disease (PD) is a neurodegenerative disorder that not only causes motor symptoms but also significant non-motor symptoms, including psychosis and catatonia. Catatonia is a rare but serious manifestation in PD patients, often exacerbated by medication changes or comorbid conditions such as acromegaly. Understanding and treating these symptoms is crucial for improving patient outcomes.
Data Highlights
Case report of a 78-year-old woman with Parkinson's disease and acromegaly who experienced complete remission of catatonia and psychotic symptoms after lorazepam treatment.
Key Findings
Lorazepam treatment led to complete resolution of catatonia and psychosis within six days.
The patient had a history of Parkinson's disease and major depressive disorder, with symptoms worsening after medication withdrawal.
Brain MRI revealed a pituitary macroadenoma, confirming the diagnosis of acromegaly.
Overall improvement in neuropsychiatric symptoms was approximately 50% after restarting levodopa and initiating lorazepam.
This case highlights the importance of recognizing catatonia and psychosis as complications of PD, especially in the context of medication changes.
Clinical Implications
Healthcare professionals should be vigilant in recognizing catatonia and psychosis in patients with Parkinson's disease, particularly following medication withdrawal. Lorazepam may be an effective treatment option for these complex neuropsychiatric symptoms, warranting consideration in similar cases.
Conclusion
Highlight the necessity for further research on lorazepam's broader applicability.
